An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).-MedSci.cn

An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).

Mandala, M; Larkin, JMG; Ascierto, PA; Del Vecchio, M; Gogas, H; Cowey, CL; Fernandez, AMA; Dalle, S; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, M; Di Giacomo, AM; Middleton, MR; Lutzky, J; Millward, M; de Pril, V; Lobo, M;

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务